Work at the University of Colorado Cancer Center led to phase II trial of efatutazone with erlotinib in patients with refractory non-small cell lung cancer. Results are reported today at the American Association for Cancer ...
Apr 8, 2014
0
0
Johns Hopkins scientists have identified a molecular marker called "Mig 6" that appears to accurately predict longer survival—up to two years—among patients prescribed two of the most widely used drugs in a class of anticancer ...
Sep 5, 2013
0
0
It's a GEMM of a system. Genetically engineered mouse models that is. Using them allows scientists to study cancer in a way that more naturally mimics how human tumors exist within the complex environment of the body.
Jul 1, 2013
0
0
An eight gene 'signature' can predict length of relapse-free survival after chemotherapy, finds new research in Biomed Central's open access journal BMC Medicine.
Apr 15, 2013
0
0
Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor (EGFR), ...
Apr 8, 2013
0
1
Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50 percent of patients may ...
Mar 7, 2013
0
0
(Medical Xpress)—A new drug combination shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included ...
Feb 19, 2013
0
0
(Medical Xpress)—Elderly patients with advanced non small cell lung cancer (NSCLC) who developed a rash within 28 days of receiving the targeted drug erlotinib (Tarceva) survived on average 6.2 months, compared to 4.1 ...
Oct 17, 2012
0
0
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...
Jun 1, 2011
0
0
Surgical resection is considered a potentially curative treatment for pancreatic adenocarcinoma, however, the five year survival rate of patients receiving this treatment is less than 20 percent. Adjuvant treatment, therefore, ...
Jun 4, 2013
0
0
